Yasir Ahmad, MD
Psychiatry · Paramus, NJNPI 1275570509
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,145 of the $39,263 with a category attached, or 81.9%. AbbVie accounts for 70.7% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2020 at $21,298 and has fallen 99.3% since, to $157 in 2025. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 493 payments — averaging $79.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- Sunovion Pharmaceuticals Inc.$7K
- Teva Pharmaceuticals USA, Inc.$652
- Supernus Pharmaceuticals, Inc.$528
- Vanda Pharmaceuticals Inc.$463
- Otsuka America Pharmaceutical, Inc.$441
- plus $3K from 17 others
What the payments were for
- Speaking & faculty fees$32,14582%
- Travel & lodging$400%
- Food & beverage$6,98818%
- Education$900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 114 | $27,750 |
| Sunovion Pharmaceuticals Inc. | 49 | $6,841 |
| Teva Pharmaceuticals USA, Inc. | 41 | $652 |
| Supernus Pharmaceuticals, Inc. | 37 | $528 |
| Vanda Pharmaceuticals Inc. | 37 | $463 |
| Otsuka America Pharmaceutical, Inc. | 37 | $441 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $414 |
| Alkermes, Inc. | 26 | $389 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $367 |
| Lundbeck LLC | 25 | $325 |
| Neurocrine Biosciences, Inc. | 17 | $229 |
| Johnson & Johnson | 11 | $159 |
| Bausch Health US, LLC | 7 | $113 |
| Corium, LLC | 7 | $105 |
| Neuronetics, Inc. | 3 | $101 |
| Almatica Pharma LLC | 6 | $82 |
| Jazz Pharmaceuticals Inc. | 6 | $80 |
| Axsome Therapeutics, Inc. | 4 | $73 |
| Idorsia Pharmaceuticals US Inc | 4 | $58 |
| Noven Therapeutics, LLC | 3 | $41 |
| Merck | 2 | $27 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,263 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 177 | $486,689 |
| AustedoDeutetrabenazine | 12 | $138,769 |
| FanaptIloperidone | 19 | $56,844 |
| LybalviOlanzapine/Samidorphan Malate | 14 | $20,886 |
| VyvanseLisdexamfetamine Dimesylate | 12 | $5,308 |
| Clomipramine Hcl | 15 | $5,120 |
| Clonazepam | 217 | $2,280 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 52 | $2,242 |
| Asenapine Maleate | 13 | $1,729 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 27 | $1,528 |
| Bupropion XlBupropion Hcl | 90 | $1,488 |
| Aripiprazole | 39 | $1,313 |
| Quetiapine Fumarate | 112 | $1,294 |
| Buspirone Hcl | 69 | $1,126 |
| Gabapentin | 102 | $1,057 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $159 | $486,689177 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $652 | $138,76912 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $463 | $56,84419 claims |
| Alkermes, Inc.Lybalvi | $389 | $20,88614 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $367 | $5,30812 claims |
| Almatica Pharma LLCSertraline Hcl | $82 | $49161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in Paramus
- Aijaz NanjianiParamus$95K
- Joel FederbushParamus$11K
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.